Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia
← catalyst calendarSponsored by Kyowa Kirin Co., Ltd. (industry) · 4151.T — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
36actual
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-05-10 | actual | When the study began enrolling |
| Primary completion | 2024-08-31 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2021-05-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Aplastic Anemia
Primary outcomes
what the primary-completion date above is the date OFHematological response at 2 years after the start of romiplostim treatment in Study 531-003/531-004
measured 2 years
Hematological response at up to 5 years after the start of romiplostim treatment in Study 531-003/531-004
measured 5 years
Permalink · 4151.T's whole pipeline · Catalyst calendar · Every registered study · What changed